Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759715 | 0.87 | PIK3CG (0.39) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL2688914 | 0.87 | PIK3CG (0.46) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL4759713 | 0.83 | PIK3CG (0.35) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL2692071 | 0.83 | PIK3CG (0.46) | PIK3CGPIK3CALMNAGAAMAPT | |
| SCHEMBL2689454 | 0.80 | LMNA (0.41) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL1770505 | 0.80 | ALDH1A1 (0.39) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL2690337 | 0.80 | LMNA (0.35) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL2689638 | 0.80 | ALDH1A1 (0.39) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL2691004 | 0.79 | LMNA (0.35) | OGAPIK3CGPIK3CALMNAGAA | |
| SCHEMBL2690998 | 0.78 | LMNA (0.34) | OGAPIK3CGPIK3CALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2421872-B1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2421872-B1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010122091-A1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | CCNA1, MKI67, CCNT1 | OGA 2113/4885PIK3CG 4396/4885PIK3CA 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.